Connect Biopharma says rademikibart cuts COPD treatment failure rate 81% in Phase 2
Connect Biopharma reported preliminary topline results from a global Phase 2 trial of rademikibart in acute COPD flare-ups, cutting post-flare treatment failures versus placebo by 81% through Week 4 and planning to seek FDA alignment for a Phase 3 registrational add-on program.
Story updates
11:10:28 AM UTC
SquawkNews
Sept 30 (Reuters) — Connect Biopharma Holdings Ltd: Connect Biopharma Announces Positive Preliminary Topline Data From Its Global Phase 2 Study Of Rademikibart As An Add-on Treatment For Acute Exacerbations In Adults With Copd And Type 2 Inflammation Connect Biopharma - Rademikibart Reduced New Moderate To Severe Copd Exacerbations By 85% Through One Month Connect Biopharma - Rademikibart Reduced Hospitalizations Or Ed Visits For Acute Copd Exacerbations By 100% Connect Biopharma - Rademikibart Well Tolerated With Lower Incidence Of Adverse Events Than Placebo Connect Biopharma - Rademikibart Reduced Treatment Failure Rate By 81% Through One Month In Phase 2 Study Connect Biopharma - To Engage Fda For Phase 3 Program For Rademikibart In Copd Source text:... Further company coverage: CNTB.O (Reuters.Briefs@thomsonreuters.com;;)